Monoaminergic Neuropathology in Alzheimer's disease
| dc.contributor.author | Šimić, Goran | |
| dc.contributor.author | Leko, Mirjana Babić | |
| dc.contributor.author | Wray, Selina | |
| dc.contributor.author | Harrington, Charles R. | |
| dc.contributor.author | Delalle, Ivana | |
| dc.contributor.author | Jovanov-Milošević, Nataša | |
| dc.contributor.author | Bažadona, Danira | |
| dc.contributor.author | Buée, Luc | |
| dc.contributor.author | Silva, Rohan de | |
| dc.contributor.author | Giovanni, Giuseppe Di | |
| dc.contributor.author | Wischik, Claude M. | |
| dc.contributor.author | Hof, Patrick R. | |
| dc.contributor.institution | University of Aberdeen.Medical Sciences | en |
| dc.contributor.institution | University of Aberdeen.Applied Medicine | en |
| dc.date.accessioned | 2017-04-12T23:29:30Z | |
| dc.date.available | 2017-04-12T23:29:30Z | |
| dc.date.embargoedUntil | 2017-04-12 | |
| dc.date.issued | 2017-04 | |
| dc.description | Acknowledgments This work was supported by The Croatian Science Foundation grant. no. IP-2014-09-9730 (“Tau protein hyperphosphorylation, aggregation, and trans-synaptic transfer in Alzheimer’s disease: cerebrospinal fluid analysis and assessment of potential neuroprotective compounds”) and European Cooperation in Science and Technology (COST) Action CM1103 (“Stucture-based drug design for diagnosis and treatment of neurological diseases: dissecting and modulating complex function in the monoaminergic systems of the brain”). PRH is supported in part by NIH grant P50 AG005138. | en |
| dc.description.status | Peer reviewed | en |
| dc.format.extent | 38 | |
| dc.format.extent | 1639812 | |
| dc.identifier | 66818067 | |
| dc.identifier | 8177319c-1ac3-49d6-a970-3681589d2b6a | |
| dc.identifier | 27084356 | |
| dc.identifier | 84971238062 | |
| dc.identifier.citation | Šimić, G, Leko, M B, Wray, S, Harrington, C R, Delalle, I, Jovanov-Milošević, N, Bažadona, D, Buée, L, Silva, R D, Giovanni, G D, Wischik, C M & Hof, P R 2017, 'Monoaminergic Neuropathology in Alzheimer's disease', Progress in Neurobiology, vol. 151, pp. 101-138. https://doi.org/10.1016/j.pneurobio.2016.04.001 | en |
| dc.identifier.doi | 10.1016/j.pneurobio.2016.04.001 | |
| dc.identifier.issn | 0301-0082 | |
| dc.identifier.other | ORCID: /0000-0003-2250-3920/work/47672877 | |
| dc.identifier.uri | http://hdl.handle.net/2164/8480 | |
| dc.identifier.vol | 151 | en |
| dc.language.iso | eng | |
| dc.relation.ispartof | Progress in Neurobiology | en |
| dc.subject | 5-hydroxytryptamine (serotonin) | en |
| dc.subject | Alzheimer's disease | en |
| dc.subject | amyloid beta (Aβ) peptide | en |
| dc.subject | blood-brain barrier | en |
| dc.subject | cerebrospinal fluid | en |
| dc.subject | epigenetics | en |
| dc.subject | locus coeruleus | en |
| dc.subject | metals | en |
| dc.subject | monoamines | en |
| dc.subject | neurofibrillary degeneration | en |
| dc.subject | non-cognitive symptoms | en |
| dc.subject | nucleus raphe dorsalis | en |
| dc.subject | phosphorylation | en |
| dc.subject | sleep-wake cycle | en |
| dc.subject | tau protein | en |
| dc.subject | RC0321 Neuroscience. Biological psychiatry. Neuropsychiatry | en |
| dc.subject.lcc | RC0321 | en |
| dc.title | Monoaminergic Neuropathology in Alzheimer's disease | en |
| dc.type | Journal article | en |
